Skip to main content

Table 1 Characteristics of five trials of IPT in schoolchildren

From: Efficacy and safety of intermittent preventive treatment for malaria in schoolchildren: a systematic review

  Clarke [24] Dicko [23] Barger [25] Nankabirwa [26] Nankabirwa [27]
Country and enrolment period Kenya (Bondo), March 2005–March 2006 Mali (Kambila), July 2002–July 2003 Mali (Kollé), September 2007–January 2008 Uganda (Tororo), February 2008–July 2008 Uganda (Tororo), February 2011–February 2012
Pattern of transmission Intense and perennial with seasonal peaks Seasonal transmission Seasonal transmission Entomological inoculation rate in 2001–2002 was 562 high-intensity year-round, estimated entomological inoculation rate of 562
Bed net use 25.5 % <5 % Not available 27.7 % 35.4 %
Study design Stratified, cluster randomized, double-blind, placebo-controlled Randomized open controlled Randomized open placebo-controlled trial Randomized, single-blinded, placebo-controlled trial Randomized, double-blind, placebo controlled trial
Number of children based on ITT 4916 262 296 780 740
Randomization Stratified cluster Individual Individual Individual Individual
IPTsc drugs and timing of delivery SP + AQ every 4 months SP bimonthly SP + AS and AQ + AS only at baseline SP, SP + AQ and DP only at baseline DP monthly and DP every 3 and 5 months
Age of study participants 5–18 years 6 months–10 years 6–13 years 8–12 years for girls and 8–14 years for boys 6–14 years
Follow-up duration 12 months 12 months 11 months 42 days 12 months
Primary endpoint Prevalence of anaemia Incidence of clinical malaria Incidence of clinical malaria and risk of asymptomatic parasitaemia Risk of asymptomatic parasitaemia at 42 days Incidence of clinical malaria over 12 months.
Secondary endpoint School performances The in vivo response of Plasmodium falciparum to SP Impact on haemoglobin concentration Impact on haemoglobin Parasite prevalence and anemia over 12 months
Control Dual placebo Passive surveillance Placebo Placebo Placebo
  1. ITT intention to treat analysis, IPT intermittent preventive treatment, SP Sulfadoxine-pyrimethamine, SP + AQ sulfadoxine-pyrimethamine plus amodiaquine, SP + AS sulfadoxine-pyrimethamine plus artesunate, AQ + AS amodiaquine plus artesunate, DP dihydroartemisinin-piperaquine